-+ 0.00%
-+ 0.00%
-+ 0.00%

INTELLIA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW FOR LONVOGURAN ZICLUMERAN (LONVO-Z) FOR HEREDITARY ANGIOEDEMA (HAE)

Reuters·09/08/2026 12:00:04

Please log in to view news